Patent Grant
9433450
The embodiments disclosed herein relate to medical devices for use in repairing a weakened or fractured bone, and more particularly to internal bone fixation devices and methods of using these devices for repairing a weakened or fractured bone.
Fracture repair is the process of rejoining and realigning the ends of broken bones. Fracture repair is required when there is a need for restoration of the normal position and function of the broken bone. Throughout the stages of fracture healing, the bones must be held firmly in the correct position and supported until it is strong enough to bear weight. In the event the fracture is not properly repaired, malalignment of the bone may occur, resulting in possible physical dysfunction of the bone or joint of that region of the body.
Until the last century, physicians relied on casts and splints to support the bone from outside the body (external fixation). However, the development of sterile surgery reduced the risk of infection so that doctors could work directly with the bone and could implant materials in the body. Currently there are several internal approaches to repair, strengthen and support a fractured bone. They include the use of internal fixation devices, such as wires, plates, rods, pins, nails, and screws to support the bone directly, and the addition of bone cement mixtures, or bone void fillers to a fractured bone.
The addition of bone cements to a fractured bone for repairing bone and, for example, joining bones are well known in the art. Conventional bone cement injection devices have difficulty adjusting or controlling the injection volume or injection rate of the bone cement in real time in reaction to cancellous bone volume and density conditions encountered inside the fractured bone. Conventional bone cements also may cause complications that include the leakage of the bone cement to an area outside of the fractured bone site, which can result in soft tissue damage as well as nerve root pain and compression.
Thus, there is a need in the art for internal bone fixation devices that repair, strengthen and support a fractured bone using minimally invasive techniques, with ease of use, and minimal damage to the bone and supporting tissues.
Internal bone fixation devices and methods for using the devices for repairing a weakened or fractured bone are disclosed herein. According to aspects illustrated herein, there is provided a device for repairing a fractured bone that includes a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, the delivery catheter having an inner void for passing at least one reinforcing material, and an inner lumen for accepting a light pipe, wherein a distal end of the inner lumen terminates in an optical lens; a conformable member releasably engaging the distal end of the delivery catheter, the conformable member moving from a deflated state to an inflated state when the at least one reinforcing material is delivered to the conformable member; and an adapter releasably engaging the proximal end of the delivery catheter for receiving the light pipe and the at least one reinforcing material.
According to aspects illustrated herein, there is provided a device for use in repairing a fractured bone that includes a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, the delivery catheter having an inner void for passing at least one reinforcing material, and an inner lumen for accepting an optical fiber; a conformable member releasably engaging the distal end of the delivery catheter, the conformable member having an inner lumen for accepting the optical fiber, the conformable member moving from a deflated state to an inflated state when the at least one reinforcing material is delivered to the conformable member; and an adapter releasably engaging the proximal end of the delivery catheter for receiving the optical fiber and the at least one reinforcing material.
According to aspects illustrated herein, there is provided a method for repairing a fractured bone that includes gaining access to an inner cavity of the fractured bone; providing a device for use in repairing the fractured bone, the device comprising a delivery catheter having an inner void for passing at least one reinforcing material and an inner lumen for accepting an optical fiber, the delivery catheter releasably engaging a conformable member having an inner lumen for passing the optical fiber; positioning the conformable member spanning at least two bone segments of the fractured bone; inserting the optical fiber into the inner lumen of the conformable member; introducing the at least one reinforcing material through the inner void of the delivery catheter for infusing the reinforcing material within the conformable member, wherein the conformable member moves from a deflated state to an inflated state; activating a light source that is connected to the optical fiber to communicate light energy into the inner lumen of the conformable member such that the at least one reinforcing material is hardened; and releasing the hardened conformable member from the delivery catheter.
The presently disclosed embodiments will be further explained with reference to the attached drawings, wherein like structures are referred to by like numerals throughout the several views. The drawings shown are not necessarily to scale, with emphasis instead generally being placed upon illustrating the principles of the presently disclosed embodiments.
While the above-identified drawings set forth presently disclosed embodiments, other embodiments are also contemplated, as noted in the discussion. This disclosure presents illustrative embodiments by way of representation and not limitation. Numerous other modifications and embodiments can be devised by those skilled in the art which fall within the scope and spirit of the principles of the presently disclosed embodiments.
Medical devices and methods for repairing a weakened or fractured bone are disclosed herein. The devices disclosed herein act as internal bone fixation devices and include a delivery catheter having an elongated shaft that terminates in a releasable conformable member. During a procedure for repairing a fractured bone, the conformable member is placed within an inner cavity of a fractured bone in a deflated state. Once in place, the conformable member is expanded from a deflated state to an inflated state by the addition of at least one reinforcing material. The at least one reinforcing material is subsequently hardened within the conformable member using light that travels and disperses from a light pipe that is placed within a light pipe conduit of the device. A light source engaging the light pipe provides the light needed for hardening the reinforcing material. In an embodiment, the light pipe is positioned in the device at a separation junction, which is an area between the releasable conformable member and the elongated shaft of the delivery catheter, to harden the reinforcing material. In an embodiment, the light pipe is positioned in the device such that the light pipe is brought into an inner lumen of the conformable member to harden the reinforcing material. The hardened conformable member may then be released from the delivery catheter and sealed to enclose the at least one reinforcing material within the conformable member. The hardened conformable member remains within the inner cavity of the fractured bone and provides support and proper orientation of the fractured bone resulting in the repair, healing, and strengthening of the fractured bone.
Reinforcing materials include, but are not limited to, bone reinforcing mixtures (such as bone cement mixtures, bone void fillers, epoxies, glues and similar adhesives), orthopedic wires, stainless-steel rods, metal pins, and other similar devices. The reinforcing material may be a natural or synthetic material for strengthening, replacing, or reinforcing of bones or bone tissue. Bone reinforcing mixtures include glues, adhesives, cements, hard tissue replacement polymers, biodegradable polymers such as PLA, PGA, and PLA-PGA copolymers, natural coral, hydroxyapatite, beta-tricalcium phosphate, and various other biomaterials known in the art for strengthening, replacing or reinforcing bones. As inert materials, bone reinforcing mixtures may be incorporated into surrounding tissue or gradually replaced by original tissue. Those skilled in the art will recognize that numerous bone reinforcing mixtures known in the art are within the spirit and scope of the presently disclosed embodiments.
A device disclosed herein may be used for the repair of bones that have weakened or fractured due to any of the bone diseases including, but not limited to osteoporosis, achondroplasia, bone cancer, fibrodysplasia ossificans progressiva, fibrous dysplasia, legg calve perthes disease, myeloma, osteogenesis imperfecta, osteomyelitis, osteopenia, osteoporosis, Paget's disease, scoliosis, and other similar diseases. A device disclosed herein may be used for the repair of bones that have weakened or fractured due to an injury, for example, a fall.
Although some of the figures show the fractured bone as a metacarpal bone in the hand, those skilled in the art will recognize that the disclosed devices and methods may be used for repairing other bones including, but not limited to, the femur, tibia, fibula, humerus, ulna, radius, metatarsals, phalanx, phalanges, ribs, spine, vertebrae, clavicle and other bones and still be within the scope and spirit of the disclosed embodiments.
The main components of an embodiment of a device for repairing a weakened or fractured bone are shown generally in
In an embodiment, the balloon portion 103 is designed to evenly contact an inner wall of a cavity in a bone. In an embodiment, the balloon portion 103 may have a pre-defined shape to fit inside the cavity in a particularly shaped bone. For example, as depicted in the embodiment of
The outer surface 122 of the balloon portion 103 may be coated with materials such as drugs, bone glue, proteins, growth factors, or other coatings. For example, after a minimally invasive surgical procedure an infection may develop in a patient, requiring the patient to undergo antibiotic treatment. An antibiotic drug may be added to the outer surface 122 of the balloon portion 103 to prevent or combat a possible infection. Proteins, such as, for example, the bone morphogenic protein or other growth factors have been shown to induce the formation of cartilage and bone. A growth factor may be added to the outer surface 122 of the balloon portion 103 to help induce the formation of new bone. Due to the lack of thermal egress of the reinforcing material in the balloon portion 103, the effectiveness and stability of the coating is maintained.
In an embodiment, the outer surface 122 of the balloon portion 103 may have ribs, ridges, bumps or other shapes to help the balloon portion 103 conform to the shape of a bone cavity. Balloons may be constructed to achieve transit within luminal cavities of bones and to expand, manipulate, and remove obstructions. In this way, the balloon portion 103 may slide easier within the luminal bodies without coming in contact with surrounding tissue. The balloon portion 103 may also be designed to be placed in a bone and to grab a fractured bone without any slippage using a textured surface with a variety of shapes such as small ridges or ribs.
In an embodiment, a water soluble glue is applied to the outer surface 122 of the balloon portion 103. When the balloon portion 103 is expanded and engages a moist bone, the water soluble glue on the outer surface 122 of the balloon portion 103 becomes sticky or tacky and acts as a gripping member to increase the conformal bond of the balloon portion 103 to the bone. Once the balloon portion 103 is inflated, the outer surface 122 of the balloon portion 103 grips the bone forming a mechanical bond as well as a chemical bond. These bonds prevent the potential for a bone slippage. The water soluble glue may be cured by any light (e.g., UV not required).
In an embodiment, the balloon portion 103 has a textured surface which provides one or more ridges that allow grabbing all portions of bone fragments of a fractured bone. In an embodiment, ridges are circumferential to the balloon portion 103 and designed to add more grab to the inflated balloon portion 103 on contact with the fractured bone. The ridges are also compressive so the ridges fold up on the fractured bone when the balloon portion 103 is completely inflated. In an embodiment, sand blasted surfacing on the outer surface 122 of the balloon portion 103 improves the connection and adhesion between the outer surface 122 of the balloon portion 103 and the inner bone. The surfacing significantly increases the amount of surface area that comes in contact with the bone resulting in a stronger grip.
The balloon portion 103 of the device 100 typically does not have any valves. One benefit of having no valves is that the balloon portion 103 may be inflated or deflated as much as necessary to assist in the fracture reduction and placement. Another benefit of the balloon portion 103 having no valves is the efficacy and safety of the device 100. Since there is no communication passage of reinforcing material to the body there cannot be any leakage of material because all the material is contained within the balloon portion 103. In an embodiment, a permanent seal is created between the balloon portion 103 that is both hardened and affixed prior to the delivery catheter 110 being removed. The balloon portion 103 may have valves, as all of the embodiments are not intended to be limited in this manner.
The balloon portion 103 of the delivery catheter 110 has a diameter ranging from about 5 mm to about 9 mm. The balloon portion 103 of the delivery catheter 110 has a length ranging from about 20 mm to about 80 mm. In an embodiment, the balloon portion 103 has a diameter of about 5 mm and a length of about 30 mm. In an embodiment, the balloon portion 103 has a diameter of about 5 mm and a length of about 40 mm. In an embodiment, the balloon portion 103 has a diameter of about 6 mm and a length of about 30 mm. In an embodiment, the balloon portion 103 has a diameter of about 6 mm and a length of about 40 mm. In an embodiment, the balloon portion 103 has a diameter of about 6 mm and a length of about 50 mm. In an embodiment, the balloon portion 103 has a diameter of about 7 mm and a length of about 30 mm. In an embodiment, the balloon portion 103 has a diameter of about 7 mm and a length of about 40 mm. In an embodiment, the balloon portion 103 has a diameter of about 7 mm and a length of about 50 mm.
In an embodiment, a stiffening member 105 surrounds the elongated shaft 101 of the delivery catheter 110, and provides rigidity over the elongated shaft 101. A pusher or stabilizer 116 can be loaded proximal to the balloon portion 103. A slip sleeve 107 can surround the stiffening member 105. In an embodiment, the slip sleeve 107 surrounds the stiffening member 105 from the proximal end 123 of the balloon portion 103 up until the pusher 116. One or more radiopaque markers or bands 130 may be placed at various locations along the balloon portion 103 and/or the slip sleeve 107. A radiopaque ink bead 133 may be placed at the distal end 121 of the balloon portion 103 for alignment of the device 100 during fluoroscopy. The one or more radiopaque bands 130, using radiopaque materials such as barium sulfate, tantalum, or other materials known to increase radiopacity, allows a medical professional to view the device 100 using fluoroscopy techniques. The one or more radiopaque bands 130 also provide visibility during inflation of the balloon portion 103 to determine the precise positioning of the balloon portion 103 and the device 100 during placement and inflation. The one or more radiopaque bands 130 permit visualization of any voids that may be created by air that gets entrapped in the balloon portion 103. The one or more radiopaque bands 130 permit visualization to preclude the balloon portion 103 from misengaging or not meeting the bone due to improper inflation to maintain a uniform balloon/bone interface.
In an embodiment, an adapter 115, such as a Tuohy-Borst adapter, engages the proximal end 102 of the delivery catheter 110. A light pipe 152 having a connector 150 for communicating light from a light source (not shown), can be introduced into one of the side-arms of the adapter 115 and passes within an inner lumen of the delivery catheter 110. In an embodiment, the light pipe 152 is an optical fiber. The optical fiber can be made from any material, such as glass, silicon, silica glass, quartz, sapphire, plastic, combinations of materials, or any other material, and may have any diameter. In an embodiment, the optical fiber is made from silica glass and may have wide-angle light dispersion of about 88 degrees. In an embodiment, the optical fiber is made from a plastic material. An adhesive system housing the reinforcing material may be introduced into another side-arm of the adapter 115, as shown in
Examples of adhesive systems include, but are not limited to, caulking gun type systems, syringe systems, bag systems that contain the bone reinforcing material where the delivery of the bone reinforcing material is controlled using a tube clamp or any other restrictor valve. In the embodiment shown in
In an embodiment, the syringe 160 is opaque and does not allow light to penetrate within the syringe 160. Having an opaque syringe 160 ensures that the reinforcing material contained in the syringe 160 is not exposed to light and will not cure in the syringe 160. The reinforcing material is of a liquid consistency, as measured in Centipoise (cP), the unit of dynamic viscosity, so the reinforcing material may be infused from the syringe 160 into the delivery catheter 110 and into the balloon portion 103. Because the reinforcing material has a liquid consistency and is viscous, the reinforcing material may be delivered using low pressure delivery and high pressure delivery is not required, but may be used.
In an embodiment, the reinforcing material is a light cure adhesive or ultraviolet (UV) adhesive. Examples of light cured materials include those commercially available from Loctite of Henkel Corporation, located in Rocky Hill, Conn. and those commercially available from DYMAX Corporation, located in Torrington, Conn. A benefit of UV curing is that it is a cure-on-demand process and that adhesives may be free of solvents and include environmentally friendly resins that cure in seconds upon exposure to long wave UV light or visible light. Different UV adhesives use photoinitiators sensitive to different ranges of UV and visible light. Being very energetic, UV light can break chemical bonds, making molecules unusually reactive or ionizing them, in general changing their mutual behavior. Visible light, for example, visible blue light, allows materials to be cured between substrates that block UV light but transmits visible light (e.g., plastics). Visible light penetrates through the adhesive to a greater depth. Since the visible light penetrates through the adhesive, curing of the adhesive increases as a greater portion of the electromagnetic spectrum is available as useful energy. Additives may be used with the UV adhesive delivery system, including, but not limited to drugs (for example, antibiotics), proteins (for example, growth factors) or other natural or synthetic additives.
The electromagnetic spectrum is the range of all possible electromagnetic radiation. The electromagnetic spectrum of an object is the frequency range of electromagnetic radiation that the object emits, reflects, or transmits. The electromagnetic spectrum extends from just below the frequencies used for modern radio (at the long-wavelength end) to gamma radiation (at the short-wavelength end), covering wavelengths from thousands of kilometers down to fractions of the size of an atom. In an embodiment, the UV adhesive is a single-component, solvent-free adhesive that will not cure until a UV light engages the adhesive, and when that occurs, the adhesive will cure in seconds to form a complete bond with a shear strength. In an embodiment, the UV adhesive is a single-component, solvent-free adhesive that will not cure until a visible light engages the adhesive, and when that occurs, the adhesive will cure in seconds to form a complete bond with a shear strength. In an embodiment, the reinforcing material exhibits a shrinkage upon cure of about 2 to about 3 percent.
UV light wavelength ranges from about 1 nm to about 380 nm, and can be subdivided into the following categories: near UV (380-200 nm wavelength; abbreviated NUV), far or vacuum UV (200-10 nm; abbreviated FUV or VUV), and extreme UV (1-31 nm; abbreviated EUV or XUV). Similarly, visible light has a wavelength spectrum of between about 380 to about 780 nm. Those skilled in the art will recognize that some UV adhesives may be activated by UV light, visible light, x-rays, gamma rays, microwaves, radio waves, long waves or any light having a wavelength less than about 1 nm, between about 1 nm and about 380 nm, between about 380 nm and about 780 nm, or greater than 780 nm, as not all embodiments are intended to be limited in that respect.
Using a UV light, the reinforcing material ensures there is no or minimal thermal egress and that the thermal egress may not be long in duration. More specifically, there is no chemical composition or mixing of materials. Using the UV light to cure the reinforcing material assists in holding broken bones in place, filling of the balloon portion, and viewing under a C arm imaging system. The reinforcing materials cure in such a way that is sufficient to hold a bone in the correct orientation. More specifically, the ability to inflate, set, adjust, orient bones, and the resulting union of the bone are available prior to hardening the reinforcing material. The introduction of the UV light starts the photoinitiator and the UV adhesive hardens. Once the UV light is introduced, the adhesive inside the balloon portion hardens and the adhesives inside are affixed in place. Until the UV light is introduced, the bone placement is not disturbed or rushed as there is no hardening of the adhesives until the light is introduced, the balloon portion may be inflated or deflated due to the viscosity of the adhesive. The adhesive may be infused or removed from the balloon portion due to the low viscosity of the adhesive. In an embodiment, the viscosity of the reinforcing material has a viscosity of about 1000 cP or less. In an embodiment, the reinforcing material has a viscosity ranging from about 650 cP to about 450 cP. Not all embodiments are intended to be limited in this respect and some embodiments may include reinforcing materials having a viscosity exactly equal to or greater than 1000 cP. In an embodiment, a contrast material may be added to the reinforcing material without significantly increasing the viscosity. Contrast materials include, but are not limited to, barium sulfate, tantalum, or other contrast materials known in the art.
Several epoxies known in the art are suitable for use as bone reinforcing materials and vary in viscosity, cure times, and hardness (durometer or shore) when fully cured. A durometer of a material indicates the hardness of the material, defined as the material's resistance to permanent indentation. Depending on the amount of resultant support that is necessary for a given bone fracture, a specific durometer UV adhesive may be chosen. Alternately, multiple UV adhesives having varying durometers may be chosen for the repair of a bone fracture and be within the scope and spirit of the presently disclosed embodiments. The durometer of a material may be altered to achieve either greater rigidity or a more malleable result. The mechanical properties of the epoxies may dictate using methods/measures that are typical for high-strength and high-impact materials including but not limited to, tensile strength and tensile modulus, tensile strength tests, ultimate modulus, Poisson's ratio, hardness measurements like Vickers and Charpy Impact which measures yield strength and toughness.
In an embodiment, the reinforcing material is cured by chemical activation or thermal activation. Chemical activation includes but is not limited to water or other liquids. In an embodiment, the reinforcing material is a drying adhesive which has a polymer dissolved in a solvent such that as the solvent evaporates, the adhesive hardens. In an embodiment, the reinforcing material is a hot or thermoplastic adhesive such that as the adhesive cools, the adhesive hardens.
The reinforcing material is not limited to the embodiments described herein and may be any material that reinforces the bone. Some materials may require or be enhanced by curing via any means, such as UV or visible light, heat, and/or addition or removal of a chemical or substance, may utilize any outside or internal processes to cure the material, or may not require curing.
In an embodiment, carbon nanotubes (CNTs) are added to the reinforcing material to increase the strength of the material. Carbon nanotubes are an allotrope of carbon that take the form of cylindrical carbon molecules and have novel strength properties. Carbon nanotubes exhibit extraordinary strength. Nanotubes are members of the fullerene structural family, which also includes buckyballs. Whereas buckyballs are spherical in shape, a nanotube is cylindrical with at least one end typically capped with a hemisphere of the buckyball structure. Nanotubes are composed entirely of sp2 bonds, similar to those of graphite. This bonding structure, which is stronger than the sp3 bonds found in diamond, provides the molecules with their unique strength. Nanotubes naturally align themselves into “ropes” held together by Van der Waals forces. Single walled nanotubes or multi-walled nanotubes may be used to strengthen the reinforcing materials.
In an embodiment, a separation area is located at the junction between the proximal end 123 of the balloon portion 103 and the elongated shaft 101. The separation area may also include an illumination band. When activated, the illumination band causes light to cure the reinforcing material located in the balloon portion 103 within the illumination band. The illumination band extends around the delivery catheter 110 and has a stress concentrator. The stress concentrator may be a notch, groove, channel or similar structure that concentrates stress in the illumination band. The stress concentrator of the illumination band may be notched, scored, indented, pre-weakened or pre-stressed to direct separation of the balloon portion 103 from the elongated shaft 101 of the delivery catheter 110 under specific torsional load. The separation area ensures that there are no leaks of reinforcing material from the elongated shaft 101 of the delivery catheter 110 and/or the balloon portion 103. The separation area seals the balloon portion 103 and removes the elongated shaft 101 of the delivery catheter 110 by making a break at a known or predetermined site (e.g., a separation area). The separation area may be various lengths and up to about an inch long. When torque (twisting) is applied to the delivery catheter 110, the elongated shaft 101 separates from the balloon portion 103. The twisting creates a sufficient shear to break the residual reinforcing material and create a clean separation of the balloon/shaft interface. The illumination band may be connected to the light source and may be activated by a separate switch. Having a distinct switch to activate the illumination band may help to prevent inadvertent delivery of light from the light pipe to cure the reinforcing material. The activation of the illumination band seals the balloon portion 103 and seals the end of the delivery catheter 110, and ensures that there is a “hard seal” of the reinforcing material at the illumination band allowing no reinforcing material to leak from the balloon portion 103 or the delivery catheter 110.
A cross-sectional view taken along line A-A of
A cross-sectional view taken along line B-B of
The light pipe 452 is introduced into a side arm of an adapter that engages a proximal end of the delivery catheter of the device. The light pipe 452 runs through an elongated shaft of the delivery catheter of the device, through the light pipe conduit. In an embodiment, the light pipe 452 will be positioned within the light pipe conduit such that it is positioned within a separation area of the device. The separation area is located at a junction between a distal end of the balloon portion and the elongated shaft. Activation of a light source, which connects to the light pipe 452 through connector 450, communicates light down the light pipe 452 to cure the reinforcing material resulting in the affixing of the balloon portion in an expanded shape. A cure may refer to any chemical, physical, and/or mechanical transformation that allows a composition to progress from a form (e.g., flowable form) that allows it to be delivered through the void in the delivery catheter, into a more permanent (e.g., cured) form for final use in vivo. For example, “curable” may refer to uncured composition, having the potential to be cured in vivo (as by catalysis or the application of a suitable energy source), as well as to a composition in the process of curing (e.g., a composition formed at the time of delivery by the concurrent mixing of a plurality of composition components).
The light pipe 652 is introduced into a side arm of an adapter that engages a proximal end of the delivery catheter of the device. The light pipe 652 runs through an elongated shaft of the delivery catheter of the device, through a light pipe conduit. In an embodiment, the light pipe 652 will be positioned within the light pipe conduit such that it is positioned within a separation area of the device. The separation area is located at a junction between a proximal end of the balloon portion and the elongated shaft. Activation of a light source, which connects to the light pipe 652 through the connector 650, communicates light down the light pipe 652 to cure the reinforcing material resulting in the affixing of the balloon portion in an expanded shape. A cure may refer to any chemical, physical, and/or mechanical transformation that allows a composition to progress from a form (e.g., flowable form) that allows it to be delivered through the void in the delivery catheter, into a more permanent (e.g., cured) form for final use in vivo. For example, “curable” may refer to uncured composition, having the potential to be cured in vivo (as by catalysis or the application of a suitable energy source), as well as to a composition in the process of curing (e.g., a composition formed at the time of delivery by the concurrent mixing of a plurality of composition components).
In an embodiment, a device for repairing a fractured bone includes a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, the delivery catheter having an inner void for passing at least one reinforcing material, and an inner lumen for accepting a light pipe, wherein a distal end of the inner lumen terminates in an optical lens; a conformable member releasably engaging the distal end of the delivery catheter, the conformable member moving from a deflated state to an inflated state when the at least one reinforcing material is delivered to the conformable member; and an adapter releasably engaging the proximal end of the delivery catheter for receiving the light pipe and the at least one reinforcing material.
In some embodiments, the intensity of light may be sufficient enough to reach the distal end of the conformable member (e.g., balloon portion) if the light pipe (e.g., optical fibers) is held in close proximity to or contacting/abutting the conformable member. By knowing the energy required to cure the reinforcing material or polymerize the monomer and calculating the distance from the light pipe to the most distal aspect of the conformable member, the inverse square law may be used to calculate how much energy will dissipate over the distance and therefore whether the light pipe can be abutted to the conformable member or need be placed within the conformable member so that it is closer to the reinforcing material. Not only is the distance from the light pipe to the reinforcing material reduced by placing the light pipe inside the conformable member, but the overall necessary intensity of light may be reduced.
In an embodiment, a device for use in repairing a fractured bone includes a delivery catheter having an elongated shaft with a proximal end, a distal end, and a longitudinal axis therebetween, the delivery catheter having an inner void for passing at least one reinforcing material, and an inner lumen for accepting an optical fiber; a conformable member releasably engaging the distal end of the delivery catheter, the conformable member having an inner lumen for accepting the optical fiber, the conformable member moving from a deflated state to an inflated state when the at least one reinforcing material is delivered to the conformable member; and an adapter releasably engaging the proximal end of the delivery catheter for receiving the optical fiber and the at least one reinforcing material.
The optical fiber 852 can each have a transmission loss (attenuation) of less than approximately 1.5% per foot, a bend radius (minimum) of approximately 6 times the fiber's 852 diameter, temperature stability of up to approximately 90° C. (194° F.), spectral transmission range of approximately 350-800 nm, an acceptance angle of approximately 80°, a refractive index core of approximately 1.48 or greater, cladding of approximately 1.34 or less and a numerical aperture of approximately 0.63. The length of the optical fiber 852 can be approximately 100 continuous feet. Splicing may be achieved in the field using a splice kit, such as the Lumenyte Splice Kit, and carefully following the instructions. Factory splicing may be an option. An optic cutter, such as Lumenyte's Optic Cutter, may be advised for straight, clean, 90° fiber cuts. These fibers may be installed by removing approximately 4 inches (10 cm) of the outer jacket (not the fluoropolymer cladding) before inserting fiber 852 into the light source. An end 850 of the fiber 852 may be near, but not touching the illuminator (light source) glass to assist in achieving maximum brightness. In some embodiments, the optical fiber 852 has some or all of the properties and/or characteristics exhibited by ESKA™ High-performance Plastic Optical Fiber: SK-10 and SK-60 and/or ESKA™ Plastic Fiber Optic & Cable Wiring, manufactured by Mitsubishi Rayon Co., Ltd., which are all available from Mitsubishi International Corporation of New York, N.Y. It should be appreciated that the above-described characteristics and properties of the optical fibers are exemplary and not all embodiments of the present invention are intended to be limited in these respects.
An optical fiber uses a construction of concentric layers for optical and mechanical advantages. The most basic function of a fiber is to guide light, i.e., to keep light concentrated over longer propagation distances—despite the natural tendency of light beams to diverge, and possibly even under conditions of strong bending. In the simple case of a step-index fiber, this guidance is achieved by creating a region with increased refractive index around the fiber axis, called the fiber core, which is surrounded by the cladding. The cladding is usually protected with at least a polymer coating. Light is kept in the “core” of the optical fiber by total internal reflection. Cladding keeps light traveling down the length of the fiber to a destination. In some instances, it is desirable to conduct electromagnetic waves along a single guide and extract light along a given length of the guide's distal end rather than only at the guide's terminating face. In some embodiments of the present disclosure, at least a portion of a length of an optical fiber is modified, e.g., by removing the cladding, in order to alter the direction, propagation, amount, intensity, angle of incidence, uniformity and/or distribution of light.
In some embodiments, optical elements may be oriented in alignment with the notches or openings in the optical fibers to adjust the light output. Such optical elements may include lenses, prisms, filters, spliters, diffusers and/or holographic films. The light source, and more specifically, the optical fibers may have some or all of the properties and features listed in U.S. Pat. No. 6,289,150, which is hereby incorporated by reference in its entirety, as not all embodiments of the present invention are intended to be limited in these respects.
In some embodiments, the optical fiber may include an optical fiber core surrounded by cladding and one or more illuminators. The illuminators may be of uniform size and shape positioned in a predetermined, spaced-apart relation, linearly, along a side of the optical fiber core. The optical fiber core may be received in a track and/or holder and/or reflector comprising a channel constructed with a reflective interior surface centered about the illuminators. The holder and/or reflector may be positioned adjacent to or in contact with the plurality of illuminators. A light source may be connected at one end of the optical fiber conduit in a conventional manner so as to cause a TIR effect. The end of the optical fiber conduit opposite the light source may include a reflective surface for reflecting back towards the light source any light remaining in the optical fiber conduit. For longer spans of optical conduit, the conduit may include a second light source.
The illuminators may include any non-uniformity, constructed into the optical fiber core during or after fabrication, that reflects or refracts light such as, for example bubbles, prisms, lenses or reflective material formed in the core during fabrication or after fabrication. Also, notches made from two cuts in the core to remove a wedge of material or singular cuts made in the core may function as the illuminators. Illuminators, such as notches or cuts may be made by using a mechanical cutter which may be capable of cutting the core uniformly and leaving a smooth, texture-free surface. A cutter suitable for this purpose may cut the core without tearing or burning the material. A cutter may have a circular disk shaped knife having a smooth, tooth-free blade that is freely rotatable about an axle located at the center of the disk. The blade may be angled at 45 degrees relative to the longitudinal axis of the core to cut a 90 degree notch wherein material having a crescent or triangular shape is removed from the core.
The notch may function as an illuminator by maximizing the TIR effect of light within the core. This may be due to the core having a different index of refraction from the ambient air in the notch which may direct the light across the core and out the opposite side of the core. Different lighting effects may be achieved by replacing the ambient air with other gases or compounds. Imperfections in the cut may direct some light into the notch. This light may reflects back through the core.
In some embodiments, where cuts are preferred over notches, the cut may be made at a uniform depth of ⅛ inch into the cladding and core and at a 45 degree angle from the horizontal, i.e., the longitudinal axis of the optical fiber. This may appear to cause the light to exit perpendicular to the longitudinal axis of the optical fiber where the optical fiber core may have an acceptance angle of approximately 81 degrees to allow light to exit. The surface of the sides of the cut may be smooth rather than rough to ensure light is refracted uniformly. The cut may form a wedge which has a gap sufficient to prevent contact between the sides of the cut during normal use. Such contact may reduce the light reflecting and/or refracting properties. In some embodiments, the cuts may be less efficient than the notches in relying on TIR to force light out of core. A holder which may fix the optical fibers in desired alignment may also act as a holder and/or reflector. In some embodiments, when the optical fiber may be round in cross section and may be placed in a nonconforming holder such as a rectilinear “U” channel where an open space is created at the bottom of the “U”, cuts may be made in the optical fibers that come in close proximity to the bottom of the “U” to maintain this configuration. In some embodiments where a conforming holder may be used, the cuts may close and alter the configuration such that efficiency of light extraction may be reduced. In some embodiments when using a conforming holder, illuminators may be made with notches sufficient to maintain an open space between the holder and notched surface.
In some embodiments, cutting notches may include using a high speed drill motor with a cutting blade sufficient to make a notch in the optical fiber such that the surface created with the notch may be smooth enough to allow total internal reflection to occur. Alignment of illuminator or illuminators with respect to the holder may determine the directionality of the light output emitted from the optical system. The shape of the cut may effect the output beam pattern of the optical system. For example, the wider the cut, the wider the output beam pattern
As with most linear fiber optics, as light is extracted from lengths of the fiber near the light source there may be less light available in subsequent lengths and this occurrence may be taken into consideration in the manufacturing process. In some embodiments, to achieve uniform lighting from the optical fiber conduit, the frequency with which the illuminators occur may increase non-linearly in relation to the length of the conduit and the distance of the illuminators from the light source. In other words, the illuminators may be closer together as the distance from the light source increases. This may compensate for the attenuation of the light due to the loss experienced from the illuminators and the natural attenuation of the optic itself. The spacing may be made progressively closer or in groups of spacing in which the groups may progressively get closer but the distance between individual illuminators within each group may remain constant. In some embodiments, the illuminators may have progressive depths to make the optical fibers transmit light evenly along its length. When illuminators are made progressively deeper, the light pattern may be altered. The deeper the cuts, the wider the light pattern may become. When illuminators are made progressively closer, the light pattern may remain the same and the light output may be increased. In some embodiments, near uniformity of light output along the length of the conduit may be achieved in part due to the changes in the spacing of the illuminators and in part due to the uniformity of the size and angle of the illuminators. A mechanical cutter may be well adapted to provide such uniformity.
While some embodiments may include continuous variations in the frequency of the cut spacing, the cutter may be adaptable to vary the frequency of the spacing at discrete intervals to minimize delays during adjustment of the spacing interval.
The illuminators may be made in optical fiber core alone before the cladding is added and/or the illuminators may be made in the cladding and the core after it has been surrounded by the cladding. In some embodiments, when the cladding is heated to tightly shrink around the core, the cladding may affect the uniformity of the illuminators in the core by either entering the notch or closing the cut thereby reducing the potential light deflecting properties of the illuminator.
The illuminators may be positioned to direct light across the greater diameter of an elliptical optical fiber core out and out through a region opposite from each of the respective illuminators. This may be accomplished by angling the notches and/or cuts to direct light from the light source through the optic core. The illuminators allow better control of escaping light by making the notches, which are positioned on one side of the optic to direct the light rather than allowing the cuts to reflect/refract light in various directions which reduces the contribution of light to a desired focusing effect.
One or more optical elements, such as diffusers, polarizers, magnifying lenses, prisms, holograms or any other element capable of modifying the direction, quantity or quality of the illumination, individually or in combination can also be added and aligned with the core-clad, notches and track or holder and/or reflector. The optical elements may be formed as separate components or formed integrally with the core, cladding and/or a jacketing material or in any combination of separate and integrally formed components. Optical elements formed integrally in the core and cladding of various shapes may create a lens and thereby affects the directionality of light from the finished product. Different optical fiber shapes may create different output beam patterns. In some embodiments, a round fiber optic may create a wider beam spread of light. In some embodiments, a wedge shaped optic may produce a collimated light beam spread. This beam spread may be due to what is believed to be a lensing effect. In some embodiments, the depth of the cut may at least intersect the focal point of the lens formed by the curvature of the optical fiber core where the light exits the core.
The optical fiber core may have any shape and the shape of the core may effect the diffusion of light. In some embodiments, the optical fiber core may be cylindrically shaped when viewed in cross-section and may form a lens that diffuses the light over a wide field of illumination. In some embodiments, the optical fiber core may have an oval or elliptical shape when viewed in cross-section and may form a lens that increases the intensity of the light within a narrower field of illumination. In some embodiments, the optical fiber core may have a wedge shape when viewed in a cross-section and may forms a lens. It will be appreciated that other shapes may be used because of their desired optical characteristics to also act as optical elements, as not all embodiments of the present invention are intended to be limited in this respect.
Alternative optical elements may also assist in achieving various lighting effects by including a separate optical element in alignment with the holder and/or reflector and the arc formed by the notch on the opposite side of the optic from the optical element. The lens optic, notch and holder and/or reflector may be aligned to direct light out of the optic and into the lens. The optical element may also be formed integrally in the jacketing material. The jacket thickness may be adjusted to achieve a desired lighting effect. Alternatively, cylindrically shaped diffusers may be included and aligned to generate other desired lighting effects. In some embodiments, a first diffuser may lower the intensity of light passing through an optical fiber and a second diffuser may increase the intensity of light passing through it. The two diffusers as thus described, may modify the intensity of light as it transmits and diverges away from the optical fiber.
In order to best make use of this kind of application specific optical lighting, it may be advisable to control the alignment of the illuminators, holder and/or reflectors and optical elements. In some embodiments, the alignment of these elements may be centered about a diameter of the fiber optic core (e.g., the diameter from and perpendicular to the center of the holder and/or reflector). It may be desirable to maintain control of this alignment along the entire length of the optical fiber conduit.
In an embodiment, a fracture repair process reinforces a weakened or fractured bone without exposing the bone through a traditional surgical incision. The presently disclosed embodiments use a minimally invasive approach by making a minor incision to gain access to the bone. Minimally invasive refers to surgical means, such as microsurgical, endoscopic or arthroscopic surgical means, that can be accomplished with minimal disruption of the pertinent musculature, for instance, without the need for open access to the tissue injury site or through minimal incisions. Minimally invasive procedures are often accomplished by the use of visualization such as fiber optic or microscopic visualization, and provide a post-operative recovery time that is substantially less than the recovery time that accompanies the corresponding open surgical approach. Benefits of minimally invasive procedures include causing less trauma because there is minimal blood loss, a reduction in surgery and anesthetized time, shortened hospitalization, and an easier and more rapid recovery. In an embodiment, a bone fixator may be placed within an intramedullary cavity of a weakened or fractured bone. By restoring and preserving bone structure, some of the presently disclosed embodiments permit additional future treatment options.
The access hole 1010 extends through a hard compact outer layer 1020 of the bone into the relatively porous inner or cancellous tissue 1025. For bones with marrow, the medullary material should be cleared from the medullary cavity prior to insertion of the device 100. Marrow is found mainly in the flat bones such as hip bone, breast bone, skull, ribs, vertebrae and shoulder blades, and in the cancellous material at the proximal ends of the long bones like the femur and humerus. Once the medullary cavity is reached, the medullary material including air, blood, fluids, fat, marrow, tissue and bone debris should be removed to form a void. The void is defined as a hollowed out space, wherein a first position defines the most distal edge of the void with relation to the penetration point on the bone, and a second position defines the most proximal edge of the void with relation to the penetration site on the bone. The bone may be hollowed out sufficiently to have the medullary material of the medullary cavity up to the cortical bone removed. There are many methods for removing the medullary material that are known in the art and within the spirit and scope on the presently disclosed embodiments. Methods include those described in U.S. Pat. No. 4,294,251 entitled “Method of Suction Lavage,” U.S. Pat. No. 5,554,111 entitled “Bone Cleaning and Drying system,” U.S. Pat. No. 5,707,374 entitled “Apparatus for Preparing the Medullary Cavity,” U.S. Pat. No. 6,478,751 entitled “Bone Marrow Aspiration Needle,” and U.S. Pat. No. 6,358,252 entitled “Apparatus for Extracting Bone Marrow.”
A guidewire (not shown) may be introduced into the bone 1002 via the access hole 1010 and placed between bone fragments 1004 and 1006 of the bone 1002 to cross the location of a fracture 1005. The guidewire may be delivered into the lumen of the bone 1002 and crosses the location of the break 1005 so that the guidewire spans multiple sections of bone fragments. As shown in
Once orientation of the bone fragments 1004 and 1006 are confirmed to be in a desired position, the UV curable glue may be hardened within the balloon portion 103, as shown in
In an embodiment, the device 100 is used to treat a hand or wrist fracture. The wrist is a collection of many joints and bones that allow use of the hands. The wrist has to be mobile while providing the strength for gripping. The wrist is complicated because every small bone forms a joint with its neighbor. The wrist comprises at least eight separate small bones called the carpal bones, that connect the two bones of the forearm, called the radius and the ulna, to the bones of the hand and fingers. The wrist may be injured in numerous ways. Some injuries seem to be no more than a simple sprain of the wrist when the injury occurs, but problems can develop years later. A hand fracture may occur when one of the small bones of the hand breaks. The hand consists of about 38 bones and any one of these bones may suffer a break. The palm or midhand is made up of the metacarpal bones. The metacarpal bones have muscular attachments and bridge the wrist to the individual fingers. These bones frequently are injured with direct trauma such as a crush from an object or most commonly the sudden stop of the hand by a wall. The joints are covered with articular cartilage that cushions the joints. Those skilled in the art will recognize that the disclosed device and methods can be used for to treat fractures to other bones, such as radius, ulna, clavicle, metacarpals, phalanx, metatarsals, phalanges, tibia, fibula, humerus, spine, ribs, vertebrae, and other bones and still be within the scope and spirit of the disclosed embodiments.
The presently disclosed embodiments may be used to treat a clavicle fracture, resulting in a clavicle reduction. The clavicle or collar bone is classified as a long bone that makes up part of the shoulder girdle (pectoral girdle). Present methods to affix a broken clavicle are limited. The clavicle is located just below the surface of the skin, so the potential for external fixation including plates and screws is limited. In addition, the lung and the subclavian artery reside below the collar bone so using screws is not an attractive option. Traditional treatment of clavicle fractures is to align the broken bone by putting it in place, provide a sling for the arm and shoulder and pain relief, and to allow the bone to heal itself, monitoring progress with X-rays every week or few weeks. There is no fixation, and the bone segments rejoin as callous formation and bone growth bring the fractured bone segments together. During healing there is much motion at the fracture union because there is not solid union and the callous formation often forms a discontinuity at the fracture site. A discontinuity in the collar bone shape often results from a clavicle fracture.
The presently disclosed embodiments and methods treat a clavicle fracture in a minimally invasive manner and may be used for a clavicle reduction or collar bone reduction. A benefit of using the disclosed device to repair a collar bone is the repair minimizes post repair misalignment of collar bone. A benefit of using the disclosed device to repair a clavicle is to resolve the patient's pain during the healing process.
Once orientation of the bone fragments 1104 and 1106 are confirmed to be in a desired position, the UV curable glue may be hardened within the balloon portion, such as by illumination with a UV emitting light source. After the UV curable glue has been hardened, the light pipe may be removed from the device 100. The balloon portion once hardened, may be released from the delivery catheter by known methods in the art, as shown in
A method for repairing a fractured bone includes gaining access to an inner cavity of the fractured bone; providing a device for use in repairing the fractured bone, the device comprising a delivery catheter having an inner void for passing at least one reinforcing material and an inner lumen for accepting an optical fiber, the delivery catheter releasably engaging a conformable member having an inner lumen for passing the optical fiber; positioning the conformable member spanning at least two bone segments of the fractured bone; inserting the optical fiber into the inner lumen of the conformable member; introducing the at least one reinforcing material through the inner void of the delivery catheter for infusing the reinforcing material within the conformable member, wherein the conformable member moves from a deflated state to an inflated state; activating a light source that is connected to the optical fiber to communicate light energy into the inner lumen of the conformable member such that the at least one reinforcing material is hardened; and releasing the hardened conformable member from the delivery catheter.
All patents, patent applications, and published references cited herein are hereby incorporated by reference in their entirety. It will be appreciated that several of the above-disclosed and other features and functions, or alternatives thereof, may be desirably combined into many other different systems or applications. Various presently unforeseen or unanticipated alternatives, modifications, variations, or improvements therein may be subsequently made by those skilled in the art which are also intended to be encompassed by the following claims.
This application is a continuation of U.S. application Ser. No. 13/616,781, filed on Sep. 14, 2012, which is a continuation of U.S. application Ser. No. 12/983,496, filed on Jan. 3, 2011, now U.S. Pat. No. 8,734,460, which is a continuation of U.S. application Ser. No. 12/262,411, filed on Oct. 31, 2008, now U.S. Pat. No. 7,879,041, which is a continuation-in-part of U.S. application Ser. No. 11/903,123, filed on Sep. 20, 2007, now U.S. Pat. No. 7,811,284, which claims the benefit of U.S. Provisional Application Ser. No. 60/858,202, filed on Nov. 10, 2006, and which also claims the benefit of U.S. Provisional Application Ser. No. 60/880,646, filed on Jan. 16, 2007, the entirety of these applications are hereby incorporated herein by reference for the teachings therein.
| Number | Name | Date | Kind |
|---|---|---|---|
| 3485520 | Alexander | Dec 1969 | A |
| 4271839 | Fogarty et al. | Jun 1981 | A |
| 4280233 | Raab | Jul 1981 | A |
| 4294251 | Greenwald et al. | Oct 1981 | A |
| 4313434 | Segal | Feb 1982 | A |
| 4341691 | Anuta | Jul 1982 | A |
| 4369772 | Miller | Jan 1983 | A |
| 4414608 | Furihata | Nov 1983 | A |
| 4422719 | Orcutt | Dec 1983 | A |
| 4433898 | Nasiri | Feb 1984 | A |
| 4462394 | Jacobs | Jul 1984 | A |
| 4466435 | Murray | Aug 1984 | A |
| 4562598 | Kranz | Jan 1986 | A |
| 4686973 | Frisch | Aug 1987 | A |
| 4697584 | Haynes | Oct 1987 | A |
| 4735625 | Davidson | Apr 1988 | A |
| 4870953 | DonMichael et al. | Oct 1989 | A |
| 4888024 | Powlan | Dec 1989 | A |
| 4892550 | Huebsch | Jan 1990 | A |
| 4904391 | Freeman | Feb 1990 | A |
| 4961424 | Kubota et al. | Oct 1990 | A |
| 4963151 | Ducheyne et al. | Oct 1990 | A |
| 4969888 | Scholten et al. | Nov 1990 | A |
| 5030093 | Mitnick | Jul 1991 | A |
| 5049157 | Mittelmeier et al. | Sep 1991 | A |
| 5085660 | Lin | Feb 1992 | A |
| 5092899 | Forte | Mar 1992 | A |
| 5102413 | Poddar | Apr 1992 | A |
| 5108404 | Scholten et al. | Apr 1992 | A |
| 5112333 | Fixel | May 1992 | A |
| 5207669 | Baker et al. | May 1993 | A |
| 5222958 | Chin | Jun 1993 | A |
| 5295733 | LeBegue | Mar 1994 | A |
| 5295962 | Crocker et al. | Mar 1994 | A |
| 5303718 | Krajicek | Apr 1994 | A |
| 5316550 | Forte | May 1994 | A |
| 5336699 | Cooke et al. | Aug 1994 | A |
| 5372598 | Luhr et al. | Dec 1994 | A |
| 5376123 | Klaue et al. | Dec 1994 | A |
| 5391144 | Sakurai et al. | Feb 1995 | A |
| 5415654 | Daikuzono | May 1995 | A |
| 5423850 | Berger | Jun 1995 | A |
| 5432876 | Appeldorn et al. | Jul 1995 | A |
| 5443468 | Johnson | Aug 1995 | A |
| 5462552 | Kiester | Oct 1995 | A |
| 5480400 | Berger | Jan 1996 | A |
| 5538514 | Hawkins | Jul 1996 | A |
| 5548676 | Savage, Jr. | Aug 1996 | A |
| 5554111 | Morrey et al. | Sep 1996 | A |
| 5556429 | Felt | Sep 1996 | A |
| 5571204 | Nies | Nov 1996 | A |
| 5658310 | Berger | Aug 1997 | A |
| 5658963 | Qian et al. | Aug 1997 | A |
| 5705181 | Cooper et al. | Jan 1998 | A |
| 5707374 | Schmidt | Jan 1998 | A |
| 5713901 | Tock | Feb 1998 | A |
| 5795353 | Felt | Aug 1998 | A |
| 5824087 | Aspden et al. | Oct 1998 | A |
| 5827289 | Reiley et al. | Oct 1998 | A |
| 5888220 | Felt et al. | Mar 1999 | A |
| 5897557 | Chin et al. | Apr 1999 | A |
| 5908433 | Eager et al. | Jun 1999 | A |
| 5972015 | Scribner et al. | Oct 1999 | A |
| 5980075 | Sheaffer | Nov 1999 | A |
| 5980253 | Oxman et al. | Nov 1999 | A |
| 5987199 | Zarian et al. | Nov 1999 | A |
| 5989230 | Frassica | Nov 1999 | A |
| 5997570 | Ligtenberg et al. | Dec 1999 | A |
| 6008264 | Ostler | Dec 1999 | A |
| 6019761 | Gustilo | Feb 2000 | A |
| 6019774 | Weiss et al. | Feb 2000 | A |
| 6033411 | Preissman | Mar 2000 | A |
| 6039762 | McKay | Mar 2000 | A |
| 6042380 | De Rowe | Mar 2000 | A |
| 6048346 | Reiley et al. | Apr 2000 | A |
| 6053917 | Sherman et al. | Apr 2000 | A |
| 6059789 | Dinger et al. | May 2000 | A |
| 6066154 | Reiley et al. | May 2000 | A |
| 6077265 | Werding et al. | Jun 2000 | A |
| 6079868 | Rydell | Jun 2000 | A |
| 6103203 | Fischer | Aug 2000 | A |
| 6110176 | Shapira | Aug 2000 | A |
| 6121341 | Sawhney et al. | Sep 2000 | A |
| 6127597 | Beyar et al. | Oct 2000 | A |
| 6136011 | Stambaugh | Oct 2000 | A |
| 6140452 | Felt et al. | Oct 2000 | A |
| 6159236 | Biel | Dec 2000 | A |
| 6179852 | Strickland et al. | Jan 2001 | B1 |
| 6195477 | Denuto et al. | Feb 2001 | B1 |
| 6200134 | Kovac et al. | Mar 2001 | B1 |
| 6217581 | Tolson | Apr 2001 | B1 |
| 6223085 | Dann et al. | Apr 2001 | B1 |
| 6224630 | Bao et al. | May 2001 | B1 |
| 6235043 | Reiley et al. | May 2001 | B1 |
| 6241734 | Scribner et al. | Jun 2001 | B1 |
| 6248110 | Reiley et al. | Jun 2001 | B1 |
| 6248131 | Felt et al. | Jun 2001 | B1 |
| 6254571 | Hart | Jul 2001 | B1 |
| 6258089 | Campbell et al. | Jul 2001 | B1 |
| 6261289 | Levy | Jul 2001 | B1 |
| 6280456 | Scribner et al. | Aug 2001 | B1 |
| 6282013 | Ostler et al. | Aug 2001 | B1 |
| 6290382 | Bourn et al. | Sep 2001 | B1 |
| 6299597 | Buscemi et al. | Oct 2001 | B1 |
| 6306177 | Felt et al. | Oct 2001 | B1 |
| 6319255 | Grundei et al. | Nov 2001 | B1 |
| 6332894 | Stalcup et al. | Dec 2001 | B1 |
| 6336914 | Gillespie, III | Jan 2002 | B1 |
| 6336930 | Stalcup et al. | Jan 2002 | B1 |
| 6358252 | Shapira | Mar 2002 | B1 |
| 6387098 | Cole et al. | May 2002 | B1 |
| 6395007 | Bhatnagar et al. | May 2002 | B1 |
| 6416531 | Chen | Jul 2002 | B2 |
| 6416737 | Manolagas et al. | Jul 2002 | B1 |
| 6419483 | Adam et al. | Jul 2002 | B1 |
| 6423055 | Farr et al. | Jul 2002 | B1 |
| 6423083 | Reiley et al. | Jul 2002 | B2 |
| 6425923 | Stalcup et al. | Jul 2002 | B1 |
| 6440444 | Boyce et al. | Aug 2002 | B2 |
| 6443988 | Felt et al. | Sep 2002 | B2 |
| 6447514 | Stalcup et al. | Sep 2002 | B1 |
| 6458375 | Gertzman et al. | Oct 2002 | B1 |
| 6478751 | Krueger et al. | Nov 2002 | B1 |
| 6482234 | Weber et al. | Nov 2002 | B1 |
| 6485512 | Cheng | Nov 2002 | B1 |
| 6494883 | Ferree | Dec 2002 | B1 |
| 6524251 | Rabiner et al. | Feb 2003 | B2 |
| 6524313 | Fassier et al. | Feb 2003 | B1 |
| 6551321 | Burkinshaw et al. | Apr 2003 | B1 |
| 6551337 | Rabiner et al. | Apr 2003 | B1 |
| 6565528 | Mueller | May 2003 | B1 |
| 6579277 | Rabiner et al. | Jun 2003 | B1 |
| 6579279 | Rabiner et al. | Jun 2003 | B1 |
| 6605056 | Eidenschink | Aug 2003 | B2 |
| 6620185 | Harvie et al. | Sep 2003 | B1 |
| 6623505 | Scribner et al. | Sep 2003 | B2 |
| 6632235 | Weikel et al. | Oct 2003 | B2 |
| 6648881 | KenKnight et al. | Nov 2003 | B2 |
| 6652547 | Rabiner et al. | Nov 2003 | B2 |
| 6652587 | Felt et al. | Nov 2003 | B2 |
| 6660013 | Rabiner et al. | Dec 2003 | B2 |
| 6679873 | Rabiner et al. | Jan 2004 | B2 |
| 6695781 | Rabiner et al. | Feb 2004 | B2 |
| 6695782 | Rabiner et al. | Feb 2004 | B2 |
| 6696073 | Boyce et al. | Feb 2004 | B2 |
| 6716216 | Boucher et al. | Apr 2004 | B1 |
| 6719773 | Boucher et al. | Apr 2004 | B1 |
| 6726691 | Osorio et al. | Apr 2004 | B2 |
| 6730048 | Hare et al. | May 2004 | B1 |
| 6733451 | Rabiner et al. | May 2004 | B2 |
| 6733513 | Boyle et al. | May 2004 | B2 |
| 6740093 | Hochschuler et al. | May 2004 | B2 |
| 6755862 | Keynan | Jun 2004 | B2 |
| 6783530 | Levy | Aug 2004 | B1 |
| 6802835 | Rabiner et al. | Oct 2004 | B2 |
| 6818018 | Sawhney | Nov 2004 | B1 |
| 6852095 | Ray | Feb 2005 | B1 |
| 6866678 | Shenderova et al. | Mar 2005 | B2 |
| 6869442 | Cheng | Mar 2005 | B2 |
| 6875212 | Shaolian et al. | Apr 2005 | B2 |
| 6885246 | Tsutsui et al. | Apr 2005 | B2 |
| 6887246 | Bhatnagar et al. | May 2005 | B2 |
| 6887275 | Carchidi et al. | May 2005 | B2 |
| 6899713 | Shaolian et al. | May 2005 | B2 |
| 6899719 | Reiley et al. | May 2005 | B2 |
| 6932843 | Smith et al. | Aug 2005 | B2 |
| 6964667 | Shaolian et al. | Nov 2005 | B2 |
| 6979341 | Scribner et al. | Dec 2005 | B2 |
| 6981981 | Reiley et al. | Jan 2006 | B2 |
| 7001431 | Bao et al. | Feb 2006 | B2 |
| 7008433 | Voellmicke et al. | Mar 2006 | B2 |
| 7048731 | Altshuler et al. | May 2006 | B2 |
| 7052498 | Levy et al. | May 2006 | B2 |
| 7077865 | Bao et al. | Jul 2006 | B2 |
| 7124067 | Ascenzi | Oct 2006 | B2 |
| 7141061 | Williams et al. | Nov 2006 | B2 |
| 7144414 | Harvie et al. | Dec 2006 | B2 |
| 7153305 | Johnson et al. | Dec 2006 | B2 |
| 7156861 | Scribner et al. | Jan 2007 | B2 |
| 7156880 | Evans et al. | Jan 2007 | B2 |
| 7169140 | Kume | Jan 2007 | B1 |
| 7215863 | Arenella et al. | May 2007 | B1 |
| 7241303 | Reiss et al. | Jul 2007 | B2 |
| 7252677 | Burwell et al. | Aug 2007 | B2 |
| 7258692 | Thelen et al. | Aug 2007 | B2 |
| 7261720 | Stevens et al. | Aug 2007 | B2 |
| 7320709 | Felt et al. | Jan 2008 | B2 |
| 7341601 | Eisermann et al. | Mar 2008 | B2 |
| 7360542 | Nelson et al. | Apr 2008 | B2 |
| 7407616 | Melikechi et al. | Aug 2008 | B2 |
| 7419450 | Ito | Sep 2008 | B2 |
| 7427295 | Ellman et al. | Sep 2008 | B2 |
| 7465318 | Sennett et al. | Dec 2008 | B2 |
| 7547319 | Segal et al. | Jun 2009 | B2 |
| 7621950 | Globerman et al. | Nov 2009 | B1 |
| 7628800 | Sherman et al. | Dec 2009 | B2 |
| 7632277 | Woll et al. | Dec 2009 | B2 |
| 7632291 | Stephens et al. | Dec 2009 | B2 |
| 7666205 | Weikel et al. | Feb 2010 | B2 |
| 7722620 | Truckai et al. | May 2010 | B2 |
| 7740656 | Mensah et al. | Jun 2010 | B2 |
| 7744555 | DiMauro et al. | Jun 2010 | B2 |
| 7766965 | Bao et al. | Aug 2010 | B2 |
| 7771476 | Justis et al. | Aug 2010 | B2 |
| 7776075 | Bruneau et al. | Aug 2010 | B2 |
| 7806900 | Rabiner | Oct 2010 | B2 |
| 7811284 | Rabiner | Oct 2010 | B2 |
| 7811286 | Medoff | Oct 2010 | B2 |
| 7811290 | Rabiner | Oct 2010 | B2 |
| 7842040 | Rabiner et al. | Nov 2010 | B2 |
| 7850711 | Stone et al. | Dec 2010 | B1 |
| 7857748 | Williams et al. | Dec 2010 | B2 |
| 7879041 | Rabiner et al. | Feb 2011 | B2 |
| 7912539 | Doty et al. | Mar 2011 | B2 |
| 7947015 | Herweck et al. | May 2011 | B2 |
| 8034071 | Scribner et al. | Oct 2011 | B2 |
| 8123807 | Kim et al. | Feb 2012 | B2 |
| 8210729 | O'Leary et al. | Jul 2012 | B2 |
| 8211121 | Quinn et al. | Jul 2012 | B1 |
| 8246628 | Rabiner | Aug 2012 | B2 |
| 8328402 | O'Leary et al. | Dec 2012 | B2 |
| 8348956 | Rabiner | Jan 2013 | B2 |
| 8366711 | Rabiner et al. | Feb 2013 | B2 |
| 8403968 | Rabiner et al. | Mar 2013 | B2 |
| 8413664 | Appling | Apr 2013 | B2 |
| 8512338 | Rabiner et al. | Aug 2013 | B2 |
| 8545499 | Lozier et al. | Oct 2013 | B2 |
| 8574233 | Rabiner et al. | Nov 2013 | B2 |
| 8668701 | Rabiner et al. | Mar 2014 | B2 |
| 8672982 | Rabiner et al. | Mar 2014 | B2 |
| 8684965 | Rabiner et al. | Apr 2014 | B2 |
| 8708955 | Tilson et al. | Apr 2014 | B2 |
| 8734460 | Rabiner | May 2014 | B2 |
| 8764761 | Truckai et al. | Jul 2014 | B2 |
| 8870965 | Rabiner et al. | Oct 2014 | B2 |
| 8906030 | Rabiner | Dec 2014 | B2 |
| 8906031 | Rabiner et al. | Dec 2014 | B2 |
| 8915966 | Rabiner et al. | Dec 2014 | B2 |
| 8936382 | O'Leary et al. | Jan 2015 | B2 |
| 8936644 | Rabiner et al. | Jan 2015 | B2 |
| 8939977 | DiPoto et al. | Jan 2015 | B2 |
| 9005254 | Rabiner et al. | Apr 2015 | B2 |
| 9050079 | Rabiner et al. | Jun 2015 | B2 |
| 9101419 | Colleran et al. | Aug 2015 | B2 |
| 9125706 | Rabiner et al. | Sep 2015 | B2 |
| 9144442 | Rabiner et al. | Sep 2015 | B2 |
| 9179959 | Rabiner et al. | Nov 2015 | B2 |
| 9216049 | Rabiner et al. | Dec 2015 | B2 |
| 9254156 | Rabiner | Feb 2016 | B2 |
| 9254195 | Rabiner et al. | Feb 2016 | B2 |
| 9265549 | Rabiner | Feb 2016 | B2 |
| 20010011174 | Reiley et al. | Aug 2001 | A1 |
| 20010044626 | Reiley et al. | Nov 2001 | A1 |
| 20020032444 | Mische | Mar 2002 | A1 |
| 20020082600 | Shaolian et al. | Jun 2002 | A1 |
| 20020156482 | Scribner et al. | Oct 2002 | A1 |
| 20020161373 | Osorio et al. | Oct 2002 | A1 |
| 20020165544 | Perren et al. | Nov 2002 | A1 |
| 20020198526 | Shaolian et al. | Dec 2002 | A1 |
| 20030028210 | Boyle et al. | Feb 2003 | A1 |
| 20030083642 | Boyd et al. | May 2003 | A1 |
| 20030105469 | Karmon | Jun 2003 | A1 |
| 20030114914 | Cheng | Jun 2003 | A1 |
| 20030156431 | Gozum et al. | Aug 2003 | A1 |
| 20030199850 | Chavez et al. | Oct 2003 | A1 |
| 20030212426 | Olson et al. | Nov 2003 | A1 |
| 20030229372 | Reiley et al. | Dec 2003 | A1 |
| 20040006341 | Shaolian et al. | Jan 2004 | A1 |
| 20040024388 | Altshuler | Feb 2004 | A1 |
| 20040034434 | Evans et al. | Feb 2004 | A1 |
| 20040059333 | Carl et al. | Mar 2004 | A1 |
| 20040059417 | Smith et al. | Mar 2004 | A1 |
| 20040092948 | Stevens et al. | May 2004 | A1 |
| 20040098015 | Weikel et al. | May 2004 | A1 |
| 20040117025 | Reindel | Jun 2004 | A1 |
| 20040133280 | Trieu | Jul 2004 | A1 |
| 20040167561 | Boucher et al. | Aug 2004 | A1 |
| 20040167625 | Beyar et al. | Aug 2004 | A1 |
| 20040225296 | Reiss et al. | Nov 2004 | A1 |
| 20040228142 | Takada et al. | Nov 2004 | A1 |
| 20040230309 | Di Mauro et al. | Nov 2004 | A1 |
| 20040247641 | Felt et al. | Dec 2004 | A1 |
| 20050010231 | Myers | Jan 2005 | A1 |
| 20050010297 | Watson et al. | Jan 2005 | A1 |
| 20050015140 | deBeer | Jan 2005 | A1 |
| 20050015148 | Jansen et al. | Jan 2005 | A1 |
| 20050018989 | Shimizu et al. | Jan 2005 | A1 |
| 20050033437 | Bao et al. | Feb 2005 | A1 |
| 20050043733 | Eisermann et al. | Feb 2005 | A1 |
| 20050043808 | Felt et al. | Feb 2005 | A1 |
| 20050049691 | Mericle et al. | Mar 2005 | A1 |
| 20050090901 | Studer | Apr 2005 | A1 |
| 20050119662 | Reiley et al. | Jun 2005 | A1 |
| 20050142315 | DeSimone et al. | Jun 2005 | A1 |
| 20050149022 | Shaolian et al. | Jul 2005 | A1 |
| 20050159749 | Levy et al. | Jul 2005 | A1 |
| 20050171604 | Michalow | Aug 2005 | A1 |
| 20050192671 | Bao et al. | Sep 2005 | A1 |
| 20050197711 | Cachia | Sep 2005 | A1 |
| 20050228260 | Burwell et al. | Oct 2005 | A1 |
| 20050234453 | Shaolian et al. | Oct 2005 | A1 |
| 20050251140 | Shaolian et al. | Nov 2005 | A1 |
| 20050284485 | Nelson et al. | Dec 2005 | A9 |
| 20060009550 | Messersmith et al. | Jan 2006 | A1 |
| 20060015105 | Warren et al. | Jan 2006 | A1 |
| 20060036253 | Leroux et al. | Feb 2006 | A1 |
| 20060084985 | Kim et al. | Apr 2006 | A1 |
| 20060100547 | Rabiner et al. | May 2006 | A1 |
| 20060100635 | Reiley et al. | May 2006 | A1 |
| 20060100706 | Shadduck et al. | May 2006 | A1 |
| 20060111726 | Felt et al. | May 2006 | A1 |
| 20060122625 | Truckai et al. | Jun 2006 | A1 |
| 20060142747 | Appling | Jun 2006 | A1 |
| 20060155296 | Richter | Jul 2006 | A1 |
| 20060173464 | Ellman et al. | Aug 2006 | A1 |
| 20060183811 | Melikechi et al. | Aug 2006 | A1 |
| 20060184246 | Zwirkoski | Aug 2006 | A1 |
| 20060195165 | Gertner et al. | Aug 2006 | A1 |
| 20060217747 | Ferree | Sep 2006 | A1 |
| 20060229617 | Meller et al. | Oct 2006 | A1 |
| 20060229625 | Truckai et al. | Oct 2006 | A1 |
| 20060247787 | Rydell et al. | Nov 2006 | A1 |
| 20060253102 | Nance et al. | Nov 2006 | A1 |
| 20060253200 | Bao et al. | Nov 2006 | A1 |
| 20060258981 | Eidenschink | Nov 2006 | A1 |
| 20060264950 | Nelson et al. | Nov 2006 | A1 |
| 20060264951 | Nelson et al. | Nov 2006 | A1 |
| 20060264952 | Nelson et al. | Nov 2006 | A1 |
| 20060265077 | Zwirkoski | Nov 2006 | A1 |
| 20060271024 | Gertner | Nov 2006 | A1 |
| 20060271061 | Beyar et al. | Nov 2006 | A1 |
| 20060276793 | Berry | Dec 2006 | A1 |
| 20060276819 | Osorio et al. | Dec 2006 | A1 |
| 20060282169 | Felt et al. | Dec 2006 | A1 |
| 20060287730 | Segal et al. | Dec 2006 | A1 |
| 20070027547 | Rydell et al. | Feb 2007 | A1 |
| 20070067032 | Felt et al. | Mar 2007 | A1 |
| 20070087031 | Ashman et al. | Apr 2007 | A1 |
| 20070100327 | Smith | May 2007 | A1 |
| 20070104416 | Shimizu et al. | May 2007 | A1 |
| 20070118143 | Ralph et al. | May 2007 | A1 |
| 20070123876 | Czartoski et al. | May 2007 | A1 |
| 20070123877 | Goldin et al. | May 2007 | A1 |
| 20070123878 | Shaver et al. | May 2007 | A1 |
| 20070161991 | Altarac et al. | Jul 2007 | A1 |
| 20070198023 | Sand et al. | Aug 2007 | A1 |
| 20070225705 | Osario et al. | Sep 2007 | A1 |
| 20070233146 | Henniges et al. | Oct 2007 | A1 |
| 20070239148 | Scheller | Oct 2007 | A1 |
| 20070255287 | Rabiner | Nov 2007 | A1 |
| 20080015500 | Herweck et al. | Jan 2008 | A1 |
| 20080019657 | Maitland et al. | Jan 2008 | A1 |
| 20080021474 | Bonutti et al. | Jan 2008 | A1 |
| 20080039854 | Rabiner | Feb 2008 | A1 |
| 20080080205 | Forrester et al. | Apr 2008 | A1 |
| 20080103505 | Fransen | May 2008 | A1 |
| 20080125784 | Rabiner et al. | May 2008 | A1 |
| 20080154266 | Protopsaltis et al. | Jun 2008 | A1 |
| 20080154368 | Justis | Jun 2008 | A1 |
| 20080154373 | Protopsaltis et al. | Jun 2008 | A1 |
| 20080183122 | Fisher et al. | Jul 2008 | A1 |
| 20080188805 | Davies | Aug 2008 | A1 |
| 20080188858 | Luzzi et al. | Aug 2008 | A1 |
| 20080234820 | Felt et al. | Sep 2008 | A1 |
| 20080249529 | Zarda et al. | Oct 2008 | A1 |
| 20080255560 | Myers et al. | Oct 2008 | A1 |
| 20080269750 | Justin | Oct 2008 | A1 |
| 20080287951 | Stoneburger et al. | Nov 2008 | A1 |
| 20080308753 | Stuba et al. | Dec 2008 | A1 |
| 20090005782 | Chirico et al. | Jan 2009 | A1 |
| 20090018524 | Greenhalgh et al. | Jan 2009 | A1 |
| 20090024166 | Carl et al. | Jan 2009 | A1 |
| 20090048629 | Rabiner | Feb 2009 | A1 |
| 20090054900 | Rabiner et al. | Feb 2009 | A1 |
| 20090076610 | Afzal et al. | Mar 2009 | A1 |
| 20090093887 | Walter et al. | Apr 2009 | A1 |
| 20090112196 | Rabiner et al. | Apr 2009 | A1 |
| 20090118833 | Hudgins et al. | May 2009 | A1 |
| 20090125028 | Teisen et al. | May 2009 | A1 |
| 20090171265 | Doty et al. | Jul 2009 | A1 |
| 20090171358 | Chang et al. | Jul 2009 | A1 |
| 20090177204 | Colleran et al. | Jul 2009 | A1 |
| 20090182336 | Brenzel et al. | Jul 2009 | A1 |
| 20090187192 | Rabiner et al. | Jul 2009 | A1 |
| 20090216232 | Buford, III et al. | Aug 2009 | A1 |
| 20090228007 | Justin et al. | Sep 2009 | A1 |
| 20090254064 | Boatman | Oct 2009 | A1 |
| 20090287309 | Walch et al. | Nov 2009 | A1 |
| 20090306589 | Tilson et al. | Dec 2009 | A1 |
| 20100076503 | Beyar et al. | Mar 2010 | A1 |
| 20100234958 | Linares | Sep 2010 | A1 |
| 20100241178 | Tilson et al. | Sep 2010 | A1 |
| 20100249942 | Goswami et al. | Sep 2010 | A1 |
| 20100256641 | Rabiner et al. | Oct 2010 | A1 |
| 20100262069 | Rabiner et al. | Oct 2010 | A1 |
| 20100262188 | Rabiner et al. | Oct 2010 | A1 |
| 20100265733 | O'Leary et al. | Oct 2010 | A1 |
| 20100318087 | Scribner et al. | Dec 2010 | A1 |
| 20100331850 | Rabiner | Dec 2010 | A1 |
| 20110004213 | Rabiner et al. | Jan 2011 | A1 |
| 20110009871 | Rabiner | Jan 2011 | A1 |
| 20110029093 | Bojarski et al. | Feb 2011 | A1 |
| 20110046746 | Rabiner et al. | Feb 2011 | A1 |
| 20110077651 | Lozier et al. | Mar 2011 | A1 |
| 20110082504 | Singhatt et al. | Apr 2011 | A1 |
| 20110098713 | Rabiner et al. | Apr 2011 | A1 |
| 20110110114 | Papac et al. | May 2011 | A1 |
| 20110112588 | Linderman et al. | May 2011 | A1 |
| 20110118740 | Rabiner et al. | May 2011 | A1 |
| 20110137317 | O'Halloran et al. | Jun 2011 | A1 |
| 20110160870 | Baumgartner et al. | Jun 2011 | A1 |
| 20110166306 | Stansbury et al. | Jul 2011 | A1 |
| 20110218626 | Krinke et al. | Sep 2011 | A1 |
| 20110268866 | Parker | Nov 2011 | A1 |
| 20110288522 | Hollowel et al. | Nov 2011 | A1 |
| 20110313356 | Rabiner et al. | Dec 2011 | A1 |
| 20120016371 | O'Halloran et al. | Jan 2012 | A1 |
| 20120029102 | Rose et al. | Feb 2012 | A1 |
| 20120041557 | Frigg | Feb 2012 | A1 |
| 20120165941 | Rabiner et al. | Jun 2012 | A1 |
| 20120259375 | Druma et al. | Oct 2012 | A1 |
| 20120262939 | O'Leary et al. | Oct 2012 | A1 |
| 20120289968 | Rabiner | Nov 2012 | A1 |
| 20120316652 | Renganath et al. | Dec 2012 | A1 |
| 20130003406 | O'Leary et al. | Jan 2013 | A1 |
| 20130006304 | Rabiner et al. | Jan 2013 | A1 |
| 20130012998 | Altarac et al. | Jan 2013 | A1 |
| 20130013008 | Rabiner et al. | Jan 2013 | A1 |
| 20130013009 | Colleran et al. | Jan 2013 | A1 |
| 20130013010 | Rabiner et al. | Jan 2013 | A1 |
| 20130018482 | Meridew et al. | Jan 2013 | A1 |
| 20130023876 | Rabiner et al. | Jan 2013 | A1 |
| 20130023877 | Rabiner et al. | Jan 2013 | A1 |
| 20130023886 | Rabiner et al. | Jan 2013 | A1 |
| 20130041472 | Rabiner et al. | Feb 2013 | A1 |
| 20130046390 | Rabiner et al. | Feb 2013 | A1 |
| 20130066326 | Rabiner et al. | Mar 2013 | A1 |
| 20130158607 | Rabiner et al. | Jun 2013 | A1 |
| 20130184715 | Rabiner et al. | Jul 2013 | A1 |
| 20140018806 | DiPoto et al. | Jan 2014 | A1 |
| 20140135847 | Rabiner et al. | May 2014 | A1 |
| 20140142581 | Rabiner et al. | May 2014 | A1 |
| 20140148813 | Rabiner et al. | May 2014 | A1 |
| 20140163453 | Rabiner et al. | Jun 2014 | A1 |
| 20140180288 | Rabiner et al. | Jun 2014 | A1 |
| 20150066028 | Rabiner et al. | Mar 2015 | A1 |
| 20150066085 | Rabiner et al. | Mar 2015 | A1 |
| 20150080900 | Rabiner et al. | Mar 2015 | A1 |
| 20150088268 | Rabiner et al. | Mar 2015 | A1 |
| 20150374498 | Rabiner et al. | Dec 2015 | A1 |
| 20160022333 | Rabiner et al. | Jan 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 40 28 466 | Mar 1992 | DE |
| 0 709 698 | May 1996 | EP |
| 2001-527437 | Dec 2001 | JP |
| 2004-526525 | Sep 2002 | JP |
| 2005-511143 | Apr 2005 | JP |
| 2006-212425 | Aug 2006 | JP |
| 9001858 | Mar 1992 | NL |
| WO 9838918 | Sep 1998 | WO |
| WO 9943266 | Sep 1999 | WO |
| 0230338 | Apr 2002 | WO |
| WO 0243628 | Jun 2002 | WO |
| WO 03047472 | Jun 2003 | WO |
| WO 2004045393 | Jun 2004 | WO |
| WO 2004058045 | Jul 2004 | WO |
| WO 2004073563 | Sep 2004 | WO |
| WO 2004112661 | Dec 2004 | WO |
| WO 2005112804 | Dec 2005 | WO |
| WO 2006016807 | Feb 2006 | WO |
| WO 2007002251 | Jan 2007 | WO |
| WO 2007059259 | May 2007 | WO |
| WO 2007075375 | Jul 2007 | WO |
| WO 2007127255 | Nov 2007 | WO |
| WO 2007127260 | Nov 2007 | WO |
| 2008021972 | Feb 2008 | WO |
| WO 2008039811 | Apr 2008 | WO |
| WO 2008063265 | May 2008 | WO |
| WO 2009059090 | May 2009 | WO |
| WO 2009064847 | May 2009 | WO |
| WO 2009082688 | Jul 2009 | WO |
| WO 2009088927 | Jul 2009 | WO |
| WO 2009131999 | Oct 2009 | WO |
| WO 2010050965 | May 2010 | WO |
| WO 2010118158 | Oct 2010 | WO |
| WO 2011060062 | May 2011 | WO |
| 2011066522 | Jun 2011 | WO |
| WO 2011071567 | Jun 2011 | WO |
| WO 2011162910 | Dec 2011 | WO |
| WO 2012051312 | Apr 2012 | WO |
| WO 2012088432 | Jun 2012 | WO |
| WO 2013013069 | Jan 2013 | WO |
| WO 2013013071 | Jan 2013 | WO |
| WO 2013013072 | Jan 2013 | WO |
| WO 2013059609 | Apr 2013 | WO |
| WO 2014011669 | Jan 2014 | WO |
| WO 2014100427 | Jun 2014 | WO |
| Entry |
|---|
| USPTO Office Action in U.S. Appl. No. 13/553,247 mailed May 1, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/297,097 mailed May 29, 2015. |
| USPTO Office Action in U.S. Appl. No. 14/171,036 mailed Jun. 1, 2015. |
| USPTO Office Action in U.S. Appl. No. 14/164,846 mailed Jun. 4, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jul. 15, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/796,085 mailed Jul. 17, 2015. |
| Jovanovic et al., “Fixion Nails for Humeral Fractures, Injury”, Int. J. Care Injured, vol. 35, Issue 11, pp. 1140-1142, Nov. 2004. |
| Maruyama et al., “Metacarpal Fracture Fixation with Absorbable Polyglycolide Rods and Stainless Steel K Wires: A Biomechanical Comparison”, Journal of Biomedical Materials Research (Applied Biomaterials), vol. 33, Issue 1, pp. 9-12, Apr. 1996. |
| Waris et al., “Bioabsorbable Miniplating Versus Metallic Fixation for Metacarpal Fractures”, Clinical Orthopaedics and Related Research, No. 410, pp. 310-319, May 2003. |
| Waris et al., “Self-Reinforced Bioabsorbable Versus Metallic Fixation Systems for Metacarpal and Phalangeal Fractures: A Biomechanical Study”, The Journal of Hand Surgery, vol. 27A, No. 5, pp. 902-909, Sep. 2002. |
| PCT International Search Report based on PCT/US07/20402 dated Apr. 1, 2008. |
| PCT International Search Report based on PCT/US07/10050 dated Apr. 17, 2008. |
| PCT International Search Report based on PCT/US07/10038 dated Aug. 27, 2008. |
| PCT International Search Report based on PCT/US08/81929 dated Jan. 12, 2009. |
| PCT International Search Report based on PCT/US08/81924 dated Feb. 9, 2009. |
| PCT International Search Report based on PCT/US08/87630 dated Feb. 24, 2009. |
| USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Apr. 29, 2009. |
| USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Mar. 11, 2010. |
| USPTO Office Action in U.S. Appl. No. 11/789,906 mailed Apr. 30, 2010. |
| USPTO Office Action in U.S. Appl. No. 11/789,907 mailed May 11, 2010. |
| USPTO Office Action in U.S. Appl. No. 11/903,123 mailed Jul. 1, 2010. |
| PCT International Search Report based on PCT/US10/30275 dated Aug. 11, 2010. |
| USPTO Office Action in U.S. Appl. No. 12/262,411 mailed Sep. 1, 2010. |
| USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Dec. 9, 2010. |
| PCT International Search Report based on PCT/US10/56219 dated Jan. 20, 2011. |
| PCT International Search Report based on PCT/US10/46003 dated May 24, 2011. |
| PCT International Search Report based on PCT/US11/38389 dated Sep. 22, 2011. |
| USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Apr. 28, 2011. |
| USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Sep. 23, 2011. |
| USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Oct. 24, 2011. |
| USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Dec. 23, 2011. |
| USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Dec. 27, 2011. |
| USPTO Office Action in U.S. Appl. No. 12/875,460 mailed Mar. 8, 2012. |
| USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Mar. 16, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Apr. 4, 2012. |
| PCT International Search Report based on PCT/US11/66871 dated May 1, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/756,014 mailed May 11, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed May 29, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Jun. 8, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Jun. 26, 2012. |
| USPTO Office Action in U.S. Appl. No. 11/964,370 mailed Jul. 6, 2012. |
| Extended European Search Report based on EP 07 75 6022 dated Jul. 19, 2012. |
| Extended European Search Report based on EP 07 75 6016 dated Jul. 18, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Aug. 1, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/858,924 mailed Aug. 2, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/886,288 mailed Aug. 15, 2012. |
| PCT International Search Report based on PCT/US12/47447 dated Oct. 2, 2012. |
| PCT International Search Report based on PCT/US12/47446 dated Oct. 15, 2012. |
| PCT International Search Report based on PCT/US12/47444 dated Oct. 18, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Oct. 25, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Nov. 9, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Dec. 3, 2012. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Dec. 14, 2012. |
| International Search Report and Written Opinion for PCT/US2012/061047 mailed Jan. 7, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Jan. 17, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Jan. 22, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/088,916 mailed Jan. 23, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Feb. 4, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/755,784 mailed Mar. 13, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/616,416 mailed Mar. 25, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/561,249 mailed Apr. 23, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Apr. 26, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/088,916 mailed May 13, 2013. |
| Supplemental European Search Report based on EP 08 87 7881 dated May 15, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/772,947 mailed Jun. 19, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/859,680 mailed Jul. 9, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/561,249 mailed Sep. 16, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/088,916 mailed Sep. 17, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/943,544 mailed Sep. 25, 2013. |
| PCT International Search Report based on PCT/US13/049773 dated Oct. 1, 2013. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Oct. 9, 2013. |
| Extended European Search Report based on EP 10 76 2390 dated Oct. 30, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Nov. 21, 2013. |
| USPTO Office Action in U.S. Appl. No. 12/983,496 mailed Feb. 5, 2014. |
| USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Feb. 13, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/617,181 mailed Feb. 25, 2014. |
| PCT International Search Report based on PCT/US13/076598 dated Mar. 19, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/655,808 mailed Mar. 27, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/553,247 mailed May 7, 2014. |
| Extended European Search Report based on EP 14156473 dated May 13, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/800,518 mailed Jun. 10, 2014. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Jun. 26, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jun. 27, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/335,110 mailed Jul. 31, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/616,781 mailed Aug. 26, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/730,521 mailed Sep. 8, 2014. |
| USPTO Office Action in U.S. Appl. No. 12/756,014 mailed Oct. 7, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/553,450 mailed Oct. 24, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/335,110 mailed Oct. 24, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/553,247 mailed Dec. 5, 2014. |
| USPTO Office Action in U.S. Appl. No. 13/553,051 mailed Dec. 23, 2014. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Jan. 14, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jan. 15, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/335,110 mailed Feb. 9, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/796,085 mailed Feb. 12, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/553,051 mailed Mar. 31, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/553,051 mailed Sep. 11, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/553,247 mailed Sep. 23, 2015. |
| USPTO Office Action in U.S. Appl. No. 14/164,846 mailed Oct. 14, 2015. |
| USPTO Office Action in U.S. Appl. No. 14/171,036 mailed Oct. 15, 2015. |
| USPTO Office Action in U.S. Appl. No. 12/262,370 mailed Oct. 22, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/796,085 mailed Nov. 27, 2015. |
| USPTO Office Action in U.S. Appl. No. 13/553,051 mailed Jan. 6, 2016. |
| USPTO Office Action in U.S. Appl. No. 13/617,557 mailed Jan. 14, 2016. |
| USPTO Office Action in U.S. Appl. No. 14/177,748 mailed Jan. 25, 2016. |
| USPTO Office Action in U.S. Appl. No. 14/535,913 mailed Feb. 22, 2016. |
| USPTO Office Action in U.S. Appl. No. 13/553,247 mailed Mar. 2, 2016. |
| Number | Date | Country | |
|---|---|---|---|
| 20150066028 A1 | Mar 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60858202 | Nov 2006 | US | |
| 60880646 | Jan 2007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13616781 | Sep 2012 | US |
| Child | 14535971 | US | |
| Parent | 12983496 | Jan 2011 | US |
| Child | 13616781 | US | |
| Parent | 12262411 | Oct 2008 | US |
| Child | 12983496 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 11903123 | Sep 2007 | US |
| Child | 12262411 | US |
